Life at the Johns Hopkins School of Medicine
Epigenetic drugs are an emerging class of cancer therapeutics. In this article, Ph.D. candidate Roshan Chikarmane introduces Foghorn Therapeutics, its co-founder, Cigall Kadoch, and the science behind their drug development program.
Next generation cancer diagnostics are poised to change the way that cancer is detected and treated. Ph.D. candidate Roshan Chikarmane shares his perspectives on the teams and technologies that are leading the charge.
Looking to level up your skill set? Ph.D. candidate Roshan Chikarmane shares a three-step process for rapidly acquiring competence in a new skill or technique: imitate, improvise and innovate.
Why leave career fulfillment up to chance, when you can master the job market through the learned experiences of those who have been there before? Check out Hopkins Biotech Podcast.
Challenges are inevitable, particularly for those working in STEM fields. Ph.D. candidate Roshan Chikarmane shares a story that demonstrates how to recognize strategic inflection points and emerge more resilient than before.
Ph.D. candidate Roshan Chikarmane identifies key drivers of rising drug prices and introduces corresponding interventions that are being undertaken by business leaders to shift industry trends toward more affordable health care.
The fruits of modern molecular biology offer us a powerful tool that allows us to engineer the genetic code of virtually any organism. Early therapeutic applications could foreshadow an inflection point for the positioning of genome engineering in modern health care.
Here’s how a group of passionate thinkers turned scholarly insights into therapies that could help millions of patients with heart failure.
The benefits of detecting and treating cancer at early developmental stages have long been observed by clinical oncologists. Colonoscopies as well as other methods for early detection have been estimated to prevent as many as 60% of deaths attributable to colorectal cancer by identifying and removing precancerous growths1. More broadly, patients with early stage cancer […]
In a 1909 manuscript titled “Ueber den jetzigen Stand der Chemotherapie” (“About the Current State of Chemotherapy”), Nobel laureate Paul Ehrlich proclaimed, “We must learn to aim in a chemical sense.” What did he mean? Ehrlich was referring to his “magic bullet” theory of chemical specificity, the observation that certain drugs can eliminate disease-causing entities […]